DaVita HealthCare Reaches New 52-Week High (DVA)
Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
NEW YORK (TheStreet) -- DaVita HealthCare Partners (DVA">DVA) hit a new 52-week high Thursday as it is currently trading at $120, above its previous 52-week high of $119.99 with 665,209 shares traded as of 2:50 p.m. ET. Average volume has been 866,600 shares over the past 30 days.
DaVita HealthCare has a market cap of $11.09 billion and is part of the health care sector and health services industry. Shares are up 7% year to date as of the close of trading on Wednesday.
DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. The company has a P/E ratio of 21.1, above the S&P 500 P/E ratio of 17.7.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
TheStreet Ratings rates DaVita HealthCare as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, increase in net income, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company shows low profit margins. You can view the full DaVita HealthCare Ratings Report.